Menu MERCK'S COMMITMENT TO HEPATITIS C An estimated 3.5 million Americans are living with chronic hepatitis C virus (HCV) infection, a disease that can lead to long-term health consequences like liver failure or liver cancer. For nearly 30 years, Merck has been at the forefront of the response to chronic HCV and our team continues to work tirelessly to advance scientific knowledge of this significant global public health issue. IN THE PAST DECADE, MERCK'S CLINICAL DEVELOPMENT PROGRAMS IN CHRONIC HCV INFECTION HAVE: ENROLLED APPROXIMATELY 10,000 PARTICIPANTS INCLUDED MORE THAN 135 CLINICAL TRIALS IN APPROXIMATELY 40 COUNTRIES What drives us to address the major public health issues in the world today is the fact that we have the opportunity and the tools available to advance scientific understanding. Dr. Eliav Barr vice president, Clinical Research, Infectious Disease MERCK IS PROUD OF ITS CONTRIBUTIONS TOWARD ADVANCING THE SCIENCE OF CHRONIC HCV Our pursuit of innovation will continue. As part of our longstanding leadership in infectious diseases, Merck is committed to scientific discovery in chronic HCV and working to broaden access to treatment. We will continue our collaborations with the scientific community and other stakeholders to accelerate our collective goal of addressing the global burden of chronic HCV. Learn more about Hepatitis C: A Silent Disease and Growing Concern Updated Oct. 2017 Copyright. © 2009-2017 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved. Forward-Looking Statement Privacy Terms of Use Site Map